| Depomed is a pharmaceutical company focused on pain and other central nervous system conditions. Co.'s business includes the following products marketed in the U.S. for various pain states: Gralise®, which is a once-daily product for the management of postherpetic neuralgia; CAMBIA®, which is a non-steroidal anti-inflammatory drug for the acute treatment of migraine attacks; Zipsor®, which is a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain; NUCYNTA® ER, which is a product for the management of pain severe enough to require daily, including neuropathic pain; and NUCYNTA® IR, which is for the management of moderate to severe acute pain in adults. We show 36 historical shares outstanding datapoints in our coverage of DEPO's shares outstanding history.
Understanding the changing numbers of DEPO shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like DEPO versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching DEPO by allowing them to research DEPO shares outstanding history
as well as any other stock in our coverage universe.